OBJECTIVES: Several studies have reported superior post-cardioplegic recovery after glutamate supplementation. The optimum dose of glutamate supplementation is unknown. The purpose of this study was to find the optimal protective concentration of glutamate supplementation in a model of ischaemia/cardioplegia and reperfusion.
INTRODUCTION
From a theoretical point of view, glutamate supplementation might be beneficial in ischaemia-reperfusion injury of the heart, including those in connection with cardioplegia. L-Glutamate has been postulated to have both anaplerotic and metabolic effects on the ischaemic heart. The beneficial effects of L-glutamate may result from the formation of a-ketoglutarate, which enters the citric acid cycle producing adenosine triphosphate, diminishing lactate production by shunting pyruvate to alanine and increased flux through the malate-aspartate shuttle reoxidizing the glycolytically formed NADH [1, 2] . It has also been suggested that the cardioprotective effects of glutamate may be mediated through an enhanced ability to destroy reactive oxygen species [3] . More recently, an important role of glutamate transporters has been discussed [4, 5] .
Several studies have reported that glutamate supplementation prior to or during cardioplegia [6] [7] [8] and during reperfusion [9, 10] improve post-cardioplegic recovery, although other experimental studies have not been able to confirm this [11, 12] . In particular, glutamate seems to be important during controlled reperfusion and resuscitation of the severely ischaemic †Deceased. myocardium [13, 14] . It has also been suggested that metabolic supplementation with glutamate is beneficial in post-cardioplegic heart failure as well as to prevent post-cardioplegic heart failure [15] .
A wide range of concentrations (from 0.5 mM to 100 mM) of L-glutamate have been used in clinical and experimental studies concerning cardioplegia and myocardial protection [6] [7] [8] [9] [10] [11] [12] 16] . During intravenous infusion postoperatively after coronary artery bypass grafting, a maximal uptake of glutamate occurred by a plasma concentration of approximately 0.2 mM [17] . Glutamate supplementation during reperfusion has been shown to improve heart function and reduce infarct size [18, 19] . The most commonly used concentration of glutamate in cardioplegic solution has been 13 mmol/l, which is in agreement with the concentration proposed and clinically applied by the Buckberg group [20] . The optimal dosage is not known, because proper dose-response studies have not been conducted either in cardioplegic solutions or in intravenous infusions to counteract acute heart failure. Knowing the optimal dose may be important to avoid unnecessarily high doses, because excessive doses of glutamate are neurotoxic [21] . Although numerous studies have studied glutamate in the cardioplegic solution, only 1 study has included the possible role of loading the heart before ischaemia [4] .
The aim of this study was to examine in an isolated, perfused rat heart model whether increasing concentrations of L-glutamate result in correspondingly improved postischaemic recovery and to find the optimal dose of glutamate supplementation. L-Glutamate has, both clinically and in experimental studies, been administered as a part of warm induction and during the cardioplegia per se, during the early reperfusion as well as a continuous infusion post-cardioplegia. It is not known whether the observed beneficial effects may be obtained by preischaemic loading, during cardioplegia or during reperfusion. Consequently different doses of glutamate were added to the perfusate during the whole perfusion period without mimicking any particular clinical situation.
MATERIALS AND METHODS
The local ethics committee for animal research approved the study. All animals received humane care in compliance with the 'Guide for Care and Use of laboratory Animals' prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).
Heart perfusion
Male Sprague-Dawley rats (250-275 g) were anaesthetized with diethyl ether and Heparin Leo V R 200 IU was injected into the femoral vein. The hearts were then excised and immersed into ice-cold Krebs-Henseleit buffer during preparation for aortic cannulation, mounted in a modified Langendorff model and perfused with the Krebs-Henseleit buffer (NaCl 118.5 mM, NaHCO 3 NO 4 Na; molecular weight 169.1 g/mol). Time between excision and start of perfusion was between 60 s and 90 s. Perfusion pressure was kept constant at 100 cm H 2 O, and the perfusate was gassed continuously with a mixture of 5% CO 2 and 95% O 2 . Heated water jackets around the perfusate reservoirs and heart chamber kept the temperature (37 C) constant during perfusion and ischaemia. Another reservoir without heated water jacket was located 80 cm above the heart containing cold (4-6 C) St. Thomas II cardioplegic solution for infusion into the coronary circulation via a side arm attached to the aortic cannula. Isovolumetric recordings of left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) were performed using a balloon introduced in the left ventricle through the left atrium. The volume of the balloon was adjusted to have a pressure of 0-2 mmHg. Left ventricular developed pressure (LVDP = LVSP -LVEDP) and [rate-pressure product = LVSP 3 heart rate (HR)] were calculated. Coronary flow (CF) was measured by collecting the coronary effluent over 1 min.
The experimental protocol is depicted in Fig. 1 . Following the start of perfusion, the hearts were stabilized for 25 min before baseline measurements were performed. Hearts that did not have an LVEDP of 0-2 mmHg, an LVSP above 60 mmHg or a HR above 240 beats/min following 20 min of stabilization were discarded. Then, 25 min of global, normothermic ischaemia was induced by clamping the inflow tubing followed by 3-min infusion of cold St. Thomas Hospital solution no. 2 corresponding to 20.6 ± 0.6 ml. Cardioplegia was given as a single infusion. After a total of 90 min of cold cardioplegic arrest, the hearts were reperfused with the Krebs-Henseleit buffer at 100 cm H 2 O for 60 min. Na-L-glutamate was present in the perfusate from the start of perfusion to the end of the reperfusion except in the control group which received no glutamate in neither the perfusate nor the cardioplegic solution. The same concentration was used in both the Krebs-Henseleit perfusate and the cardioplegic solution.
To avoid hyperosmolarity and too high concentrations of sodium, amounts of NaCl equimolar to the added amount of Na-L-glutamate were removed from the perfusate and the cardioplegic solution. Hence, the sodium concentration was kept constant in all the experiments performed.
Experimental design
The following groups were studied:
Group control (n = 10): no Na-L-glutamate was added to neither the perfusate nor the cardioplegic solution. Group-001 (n = 9): 0.01 mM Na-L-glutamate was added to both the perfusate and the cardioplegic solution. Group-01 (n = 10): 0.1 mM Na-L-glutamate was added. Group-1 (n = 10): 1 mM Na-L-glutamate was added. Group-10 (n = 10): 10 mM Na-L-glutamate was added. Group-20 (n = 9): 20 mM Na-L-glutamate was added. Group-30 (n = 10): 30 mM Na-L-glutamate was added. Group-100 (n = 9): 100 mM Na-L-glutamate was added.
The time for spontaneous increase of left ventricular pressure ('contracture') during normothermic ischaemia, as well as the maximal pressure at the end of normothermic ischaemia, was registered. Measurements of LVSP, LVEDP, HR and CF and calculations of LVDP and rate-pressure product were performed just prior to induction of normothermic ischaemia at 20 and 25 min of stabilization and after 2, 5, 10, 15, 20, 30, 40 and 60 min of reperfusion. After 25 min of stabilization and at 1, 2, 5, 10, 15, 20, 30 and 60 min of reperfusion, samples of the coronary effluent were collected and frozen (-80 C) for subsequent analysis. The perfusate was collected at the beginning and at the end of perfusion to verify the correct glutamate concentrations. At the end of reperfusion, the free wall of the left ventricle was rapidly excised, immediately plunged into liquid nitrogen and stored at -80 C for later measurements of glycogen, lactate and glutamate.
Analysis and calculations of metabolic parameters
In the perfusate and the coronary effluent, glucose [22] , lactate [23] and glutamate [24] were measured and the exchange across the myocardium was calculated as the difference between inflow concentration and the outflow concentration times CF.
The metabolites were extracted from the myocardial biopsies using 500 ll of 0.42 M perchloric acid. The samples were homogenized mechanically on ice bath with a Teflon pestle, and additional 1500 ll perchloric acid was added prior to centrifugation at 0 C (3000 r/min). Tissue glycogen content was determined following precipitation of glycogen from the supernatant of the perchloric acid dissolved tissue homogenate on filter paper with subsequent degradation of the precipitated glycogen by amyloglucosidase and enzymatic determination of the resultant [25] . Tissue concentrations of lactate and glutamate were determined enzymatically as described earlier for the perfusate samples.
Statistical analyses
The statistical analyses were performed with computerized statistical package (Statistica 6.0, StatSoft, Inc., Tulsa, OK, USA). Normality of the data in the individual groups, and equality of variances within and between groups were tested. Inter-group comparisons at 1 time point were performed using 1-way analysis of variance. Comparisons of functional parameters between groups were performed in the time course from 20 min to 60 min of reperfusion, when all the hearts were beating, while the metabolite exchange was compared during the entire reperfusion period using 2-way analysis of variance with repeated measurements on 1 factor. The analysis of variance tests were followed by the Tukey's honestly significant difference post hoc test for unequal n. All values in tables as well as in the figures were shown as mean ± SEM.
RESULTS

Functional parameters
The control group had zero glutamate and any effect of glutamate per se on heart function would be observed in the baseline values of the different groups before ischaemia. No effect of different glutamate concentrations was observed in the baseline situations (P = 0.06).
During normothermic ischaemia, the spontaneous pressure rise of the left ventricle was significantly delayed (P = 0.02), and the magnitude of pressure rise was reduced (P = 0.07) in Group-100 when compared with the control group (Fig. 2 ). There were no important differences in the other groups compared with the controls. During reperfusion, LVDP was significantly higher in Groups 0.1, 1, 10, 20 and 30 than in Groups 0 and 0.01 (Fig. 3) . However, LVDP did not differ between Group 100 and the other groups. LVEDP markedly increased during reperfusion. Compared with the controls and Group 0.01, LVEDP was significantly lower in the other groups (Fig. 3) . CF was significantly increased in all the glutamate-enriched groups (Table 1) when compared with the controls. No inter-group differences were found for rate-pressure product, LVSP or HR (Table 1 ). Inter-group differences were analysed using 1-way analysis of variance. The P-values relate to the overall data.
Myocardial metabolism
At the start of reperfusion, glucose uptake increased significantly in all groups compared with the precardioplegic perfusion period but decreased rapidly to about zero during early reperfusion (Table 2) . No difference between the groups was observed. At the onset of reperfusion, a significant lactate release occurred. Lactate release diminished to about 1 mmol/min after 60 min of reperfusion without any inter-group differences ( Table 1) .
The myocardial glutamate content was similar in Groups 0-1 with values of approximately 2-4 nmol/mg. It increased in a dose-related manner compared with the controls when the hearts were perfused with higher glutamate concentrations (10-100 mM) (P < 0.0001) (Fig. 4) . The content of glycogen was higher in Group 100 than in the controls (P = 0.02) (Fig. 4) . No inter-group difference in myocardial lactate content was found (P = 0.30, data not shown).
DISCUSSION
In this study, using isolated perfused rat hearts exposed to normothermic ischaemia prior to a period of cold, crystalloid cardioplegic arrest, we demonstrated that even low concentrations Figure 3 : Left ventricular developed pressure and left ventricular end-diastolic pressure (mean ± SEM) during preischaemic stabilization and postischaemic during reperfusion after normothermic ischaemia and cold cardioplegia in isolated perfused rat hearts. Groups (n = 9-10) perfused with concentrations of glutamate in the perfusate from 0 to 100 mM. Inter-group differences were analysed using 2-way analysis of variance with repeated measurement on 1 factor.
(0.1-1.0 mM) of Na-L-Glutamate improved post-cardioplegic recovery of cardiac function. Because of the existing confusion as to when to administer L-glutamate, we chose to administer L-glutamate during the entire experimental course of this study: in the perfusate before ischaemia and cardioplegia, in the cardioplegic solution and during reperfusion. This meant that the hearts were loaded with glutamate prior to ischaemia/cardioplegia. There are no studies indicating to which extent this might be important. Based on our findings that 1 mM may be optimal, the next step will be to add glutamate before ischaemia/cardioplegia, during cardioplegia, during reperfusion or combine any 2 of these.
Surprisingly, we observed no further improvement when glutamate concentrations above 1.0 mM were administered with the perfusate. Consequently, the commonly used concentration of 10-20 mM glutamate in the cardioplegic solutions may be of an unnecessary magnitude, as even a moderate increase from the normal glutamate level in plasma has a beneficial effect during initial reperfusion [10] . The most extreme concentration was 100 mM used in a single study [16] . Theoretically, however, we cannot exclude whether the lack of glutamate in the perfusate, in contrast to the blood of the intact organism, may have created a false beneficial effect when glutamate is supplemented with the perfusate. On the other side, because glutamate is free in blood, the active concentration in blood and a crystalloid perfusate is the same one. However, it may not be that surprising that a concentration in the perfusate of 1 mM had a profound effect; after all, it is 30 times higher than the normal plasma concentration (0.038 ± 4 mM) [26] .
The lowest concentrations of L-glutamate tested in isolated models with beneficial effects during cardiac ischaemia is 0.5 mM in isolated hearts from spontaneously hypertensive rats [4] and 2 mM administered during post-cardioplegic reperfusion in isolated blood-perfused pig hearts [10] . Experiments of anoxia and hypoxia in the isolated rabbit heart septum and hearts, respectively, have shown a beneficial effect of 1 mM of L-glutamate on mechanical recovery [27, 28] . In this study, only the highest 263 ± 7 270 ± 10 259 ± 14 Coronary flow (ml/min) Control 13.1 ± 0.7 12.8 ± 0.7 6.4 ± 0.5 6.7 ± 0.6 7.6 ± 0.6 7.8 ± 0.6 7.5 ± 0. concentration of 100 mM resulted in delayed onset of left ventricular pressure rise ('contracture'), which even tended to be attenuated during ischaemia, indicating an anti-ischaemic effect of such high doses. However, the amelioration of contracture was not reflected in additional improved post-cardioplegic function, but myocardial glycogen content was increased in these hearts at the end of reperfusion compared with the other groups. Functional recovery in this group of hearts was delayed, but during the last 30 min of reperfusion, it was similar to the other glutamate-enriched groups. The reason for this delay might be the lower concentration of chloride in the 100 mM group due to the substitution of chloride by glutamate affecting the action potential. Improved post-cardioplegic recovery following glutamate supplementation is in accordance with several clinical trials. In patients with stable angina pectoris who received glutamate either orally or intravenously, it was demonstrated that plasma concentrations of glutamate from 0.13 mM to 0.50 mM corresponding to an increase of the normal plasma with a factor of 4-12 resulted in increased duration of exercise and delayed onset of ST depression in a dose-related manner [26] . In patients undergoing coronary artery bypass grafting [17] , intravenous infusion of L-glutamate was administered 1-2 h postoperatively resulting in whole blood values of glutamate of up to 394 lmol/l (basal level 103 lmol/l). Maximal uptake of glutamate occurred, when the blood level was 172 lmol, approximately 70% above the normal level. This increment in blood concentration of glutamate resulted in a higher cardiac index and stroke volume index compared with a control group [29] . Together with these clinical studies, this study supports the use of low doses of L-glutamate. Low doses of glutamate might be clinically important when it is given as an intravenous infusion due to the well-known neurotoxicity of high glutamate concentrations [21] . Groups were perfused with increasing concentrations of L-glutamate (from 0 to 100 mM) as shown in the column to the left. Stab 25 indicates 25 min of stabilization prior to ischaemia and cardioplegia, whereas 1, 2 and 60 represent minutes of reperfusion. Inter-group differences during reperfusion were analysed by 2-way analysis of variance with repeated measurements on 1 factor. There were no significant differences in baseline values.
Figure 4:
Myocardial content of glutamate and glycogen at the end of reperfusion in isolated perfused rat hearts undergoing normothermic ischaemia followed by cold cardioplegia. Groups (n = 9-10) were perfused with different concentrations of glutamate in the perfusate from 0 to 100 mM. The data were presented as mean (middle point), and the error bars are the SEMs values. Inter-group differences were analysed using 1-way analysis of variance, and the P-values are overall values.
In our protocol, 25 min of normothermic ischaemia was induced before administration of cold cardioplegia. The reason for this was 3-fold: Firstly, cold cardioplegia in the healthy rat heart must be maintained for at least 6-8 h to obtain a significant functional impairment [30] . Secondly, myocardial protection with glutamate may be most important during resuscitation of the ischaemic myocardium. It has been claimed that the reason why some studies have not been able to show any effect of L-glutamate have been the use of healthy hearts [28] , as glutamate might be most important in the resuscitation of already compromised myocardium [8, 13, 14] .
Limitations
Studies in isolated hearts from rodents perfused with a crystalloid solution may not reproduce the setting of heart surgery in patients. This study only shows that 1 mM of glutamate is optimal in this model of ischaemia/cardioplegia in isolated, perfused rat hearts. We cannot say when glutamate should be administered in relation to the ischaemic insult to obtain the best protection.
CONCLUSIONS
This dose-response study demonstrated improved postischaemic and post-cardioplegic functional recovery at low concentrations of Na-L-glutamate, and the optimal concentration appears to be 1 mM in this model. The optimal time of glutamate administration is still unknown, however, when we have an 'expected' ischaemia like cardioplegia, it might be optimal to give it like we did: before, during ischaemia and during reperfusion. Future studies in large animals followed by clinical studies are necessary to determine the optimal concentration(s) of glutamate for cardioplegia and for systemic administration. Such studies should also elucidate the importance of preischaemic loading of the heart with glutamate, optimal concentrations of glutamate in vivo and administration during the reperfusion period as well as during cardioplegia.
